<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 16, 2000
ARIAD PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
DELAWARE 0-21696 22-3106987
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
26 LANDSDOWNE STREET
CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code:
(617) 494-0400
<PAGE> 2
ITEM 5. OTHER EVENTS.
On October 16, 2000, the Registrant announced the initial results of in
vivo studies on its small-molecule osteoporosis drug candidate which inhibited
bone breakdown and stimulated new bone formation. Clinical trials of the
Registrant's new osteoporosis product candidate are being planned for next
year.
The foregoing description is qualified in its entirety by reference to the
Registrant's Press Release dated October 16, 2000, a copy of which is attached
hereto as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(a) Financial statements of business acquired. Not applicable.
(b) Pro forma financial information. Not applicable.
(c) Exhibits.
99.1 The Registrant's Press Release dated October 16, 2000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ARIAD PHARMACEUTICALS, INC.
By: /s/ Jay R. LaMarche
--------------------
Jay R. LaMarche
Executive Vice President and
Chief Financial Officer
Date: October 16, 2000
2
<PAGE> 3
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
------- -----------
99.1 The Registrant's Press Release dated October 16, 2000.
